News - Page 3 of 13 - Leukaemia Care

2nd February 2024

Service closure – Health Unlocked Online Forum

After thorough consideration and evaluation, we want to inform you that Leukaemia Care's HealthUnlocked Online Forum Service will be closing on the 30th April 2024.

20th October 2023

Leukaemia Care successfully campaigns for nationwide access to new chronic lymphocytic leukaemia treatment

The National Institute for Health and Care Excellence (NICE) and Scottish Medicines Consortium (SMC) have announced the approval of zanubrutinib on the NHS for patients with chronic lymphocytic leukaemia (CLL) in all nations of the UK.

9th October 2023

Leukaemia Care successfully campaigns for a new treatment for patients with cytomegalovirus (CMV) in Scotland

Today, the Scottish Medicines Consortium (SMC) has announced the approval of maribavir (Livtencity), a new medicine for adults with a post-transplant CMV infection that is resistant to current treatments.

9th October 2023

Leukaemia Care successfully campaigns for access to potential curative treatment for adult ALL patients in Scotland

Today, the Scottish Medicines Consortium (SMC) has approved CAR-T therapy on the NHS in Scotland for all suitable adults over 25 with acute lymphoblastic leukaemia (ALL).

21st September 2023

Chief Executive Zack Pemberton-Whiteley announces departure

Chief Executive, Zack Pemberton-Whiteley, will be leaving Leukaemia Care.

14th September 2023

Leukaemia Care and MPN Voice join forces to successfully campaign for new leukaemia treatment

Today the National Institute for Health and Care Excellence (NICE) announces the approval of ruxolitinib on the NHS in England for patients with polycythemia vera.

11th September 2023

Leukaemia Care successfully campaigns for equal access in Scotland to a new treatment for CLL patients

Today, the Scottish Medicines Consortium (SMC) has announced the approval of ibrutinib in combination with venetoclax on the NHS in Scotland for patients with chronic lymphocytic leukaemia (CLL).

10th July 2023

Leukaemia Care successfully campaigns for equal access in Scotland to a new maintenance treatment for AML patients

Leukaemia Care campaigns for the Scottish Medicines Consortium (SMC) to approve oral azacitidine on the NHS in Scotland for adults with acute myeloid leukaemia (AML).

10th July 2023

Leukaemia Care successfully campaigns for access to a new treatment for patients with cGvHD in Scotland

Leukaemia Care campaigns for the Scottish Medicines Consortium (SMC) to approve belumosudil (Rezurock) on the NHS in Scotland.

10th July 2023

Scottish Medicines Consortium (SMC) decides not to approve treatment for PV patients in Scotland

The SMC has decided not to approve Besremi, also known as ropeginterferon alfa-2b, for use on the NHS in Scotland. This treatment is a monotherapy, intended to treat adult patients with polycythaemia vera (PV), without symptoms of an enlarged spleen.